Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus

Author:

Yen Fu-Shun1,Wang Shiow-Ing23,Hsu Chih-Cheng4567,Hwu Chii-Min89,Wei James Cheng-Chung31011

Affiliation:

1. Dr Yen’s Clinic, Taoyuan, Taiwan

2. Center for Health Data Science, Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan

3. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan

4. Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan

5. Department of Health Services Administration, China Medical University, Taichung, Taiwan

6. Department of Family Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan

7. National Center for Geriatrics and Welfare Research, National Health Research Institutes, Yunlin County, Taiwan

8. Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

9. Department of Medicine, National Yang-Ming Chiao Tung University School of Medicine, Taipei, Taiwan

10. Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung City, Taiwan

11. Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan

Abstract

ImportanceLupus nephritis is a major complication of systemic lupus erythematosus (SLE). Randomized clinical trials have shown nephroprotective and cardioprotective effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is).ObjectiveTo investigate whether the use of SGLT2is is associated with the onset and progression of lupus nephritis and other kidney and cardiac outcomes in patients with SLE and type 2 diabetes.Design, Setting, and ParticipantsThis multicenter cohort study used the US Collaborative Network of the TriNetX clinical data platform to identify patients with SLE and type 2 diabetes from January 1, 2015, to December 31, 2022. Data collection and analysis were conducted in September 2023.ExposuresIndividuals were categorized into 2 groups by SGLT2i use or nonuse with 1:1 propensity score matching.Main Outcomes and MeasuresThe Kaplan-Meier method and Cox proportional hazards regression models were used to calculate the 5-year adjusted hazard ratios (AHRs) of lupus nephritis, dialysis, kidney transplant, heart failure, and mortality for the 2 groups.ResultsFrom 31 790 eligible participants, 1775 matched pairs of SGLT2i users and nonusers (N = 3550) were selected based on propensity scores. The mean (SD) age of matched participants was 56.8 (11.6) years, and 3012 (84.8%) were women. SGLT2i users had a significantly lower risk of lupus nephritis (AHR, 0.55; 95% CI, 0.40-0.77), dialysis (AHR, 0.29; 95% CI, 0.17-0.48), kidney transplant (AHR, 0.14; 95% CI, 0.03-0.62), heart failure (AHR, 0.65; 95% CI, 0.53-0.78), and all-cause mortality (AHR, 0.35; 95% CI, 0.26-0.47) than SGLT2i nonusers.Conclusions and RelevanceIn this cohort study of patients with SLE and type 2 diabetes, SGLT2i users had a significantly lower risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality than nonusers. The findings suggest that SGLT2is may provide some nephroprotective and cardioprotective benefits.

Publisher

American Medical Association (AMA)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Lupus Nephritis from Pathogenesis to New Therapies: An Update;International Journal of Molecular Sciences;2024-08-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3